Several Biotech stocks today showed some positive traction with relatively little happening after the GDP numbers were released this morning. Athersys (Nasdaq: ATHX) was definitely the most active of the bunch after announcing positive Phase I data from a study for their stem cell product MultiStem in the treatment of heart damage caused by heart attack. WBB Securities promptly upgraded ATHX from “buy” to “strong buy.”
The top five percentage gainers from the biotechnology sector:
- Athersys (Nasdaq: ATHX) was up 7% to $3.12 per share on heavy volume
- Curis (Nasdaq: CRIS) was up 8% to $1.75 per share on moderate volume
- Threshold Pharmaceuticals (Nasdaq: THLD) was up 12% to $1.52 per share on light volume
- AVEO Pharmaceuticals (Nasdaq: AVEO) was up 8% to $7.72 per share on light volume
- CombiMatrix (Nasdaq: CBMX) was up 6% to $2.87 per share on light volume
Even though the volume was relatively light, as it always is on a Friday, the biotech sector offered investors a chance to get some good buys and capitalize on a quiet market.
Tags: athx, biotech, nasdaq, penny stocks, stocks, strong buys, trading
2 Responses
-
Penny Payday Says:
Penny PayDay – Biotech Friday: ATHX Jumps after Upgrade to Strong Buy. http://tinyurl.com/285p67l #stocks
-
Penny Payday Says:
Biotech Friday: ATHX Jumps after Upgrade to Strong Buy http://f.ast.ly/BefH2